drugset / Trial / NCT00005795

Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia

NCT00005795

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have acute myeloid leukemia.

Timeline

Start
2000-02
Primary completion
2002-07
Completion
2002-07

Drugs

EvaluationDrugModalityDoseRoute
Subject arsenic trioxide Small molecule Intravenous

Indications